PMID: 9176029Apr 1, 1997Paper

Gene therapy for diabetes mellitus

Clinical Science
K Docherty

Abstract

1. This review describes experimental approaches to test the feasibility of using gene therapy to administer insulin to type 1 and type 2 diabetic patients. Two approaches, i.e. ex vivo and in vivo transfer of the insulin gene, are described. 2. Substantial progress has been made in recent years in engineering glucose-responsive beta-cell lines that have been genetically engineered to proliferate or differentiate in response to appropriate extracellular signals. 3. Non-beta-cell lines have been engineered to constitutively secrete insulin at a constant rate. These cells may improve glycaemic control in patients over longer periods when used in combination with insulin injections. Engineering glucose-stimulated insulin secretion in such cells has proved extremely difficult and several genes may he required. 4. In vivo transfer of the insulin gene to animals results in improved control of diabetes. However, for safety reasons this approach may have limited use in the treatment of diabetes in humans.

Citations

Jul 23, 1999·Annals of the New York Academy of Sciences·C J WeberJ Kapp
Aug 10, 2000·Metabolic Engineering·F WangB C Buckland
Apr 24, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jun TianStelios T Andreadis
Dec 6, 2002·Drugs·Nikolai PetrovskyDesmond A Schatz
Sep 27, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Philipp C NettTausif Alam
Jan 3, 2006·Diabetes Technology & Therapeutics·Seda KizilelEmmanuel Opara
Apr 2, 2002·World Journal of Gastroenterology : WJG·Xin-Yu QinZe-Guang Han

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.